CCN5, a matricellular protein, has been found to reverse established cardiac fibrosis in heart failure models, according to a study led by Roger J. Hajjar, MD, Professor of Medicine and Director of the Cardiovascular Research Center at the Icahn School…
Announcement on Proposed Conversion of Japanese Subsidiary into the Holding Company of Acucela Inc. through Triangular Merger, Application for Listing of Shares as a Domestic Company, and Partial Amendment to the Bylaws of Acucela Inc.
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (located in Seattle, Washington, U.S.A.; the “Company”) (TOKYO:4589), a clinical stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, has unanimously resolved at its board of directors meeting held on March 28, 2016 (Pacific Daylight Time) to (i) convert Acucela Japan Kabushiki Kaisha (the “Japan Holding Company”), which was established as a
Uncategorized
Minimal regression seen after intrastromal astigmatic keratotomy
Femtosecond laser-assisted cataract surgery with and without non-penetrating femtosecond laser intrastromal astigmatic keratotomy both yielded “small but statistically significant” regressions in surgically induced astigmatism over time, according to a study.The prospective study included 263 eyes that underwent femtosecond laser-assisted cataract surgery; 87 eyes underwent concurrent intrastromal astigmatic keratotomy (ISAK) and a comparator group of 176 eyes did not.
Ocular TherapeutixTM to Host Investor Day on April 6, 2016
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the Company will …
Uncategorized
Publication Exclusive: Scrutinize use of perioperative medications to help eliminate dry eye after surgery
Dry eye has always been a big nuisance for surgeons. Most of the time we are dealing with fast, straightforward decisions and with procedures that lead to an immediate result, usually positive. Complications may eventually develop, but most of them are…
Uncategorized
Omeros reports $75.1 million net loss in 2015
Omeros reported a net loss of $75.1 million, or $2.00 per share, in 2015 compared with $73.7 million, or $2.22 per share, in 2014, according to a company press release. Total costs and expenses were reported at $84.7 million in 2015 compared with $70.5…